Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Look Back At 2010: In Search Of New Biopharma Models

Executive Summary

2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.

You may also be interested in...



AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures

AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.

AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures

AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.

Oncology Dealmaking In The Wake Of Changing Regulatory And Reimbursement Decisions

As big drugmakers move wholeheartedly into oncology, changing regulatory and reimbursement standards have dramatic implications for dealmaking - especially for smaller venture-backed start-ups who hope to sign lucrative alliances or M&A deals with deeper-pocketed partners.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel